Journal article
A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial Methodological considerations
Abstract
BACKGROUND: Zoledronic acid is an intravenous once yearly bisphosphonate that has been shown to be effective and safe in improving BMD (bone mineral density) and reducing fracture risk in controlled clinical trials. IVORY is a Canadian post marketing study aiming at assessing real-life effectiveness, health care resource utilization, safety and compliance to treatment with zoledronic acid in comparison to orally administered bisphosphonates …
Authors
Brown JP; Adachi JD; Kendler DL; Rigal R; Deutsch G; Leclerc JM
Journal
Contemporary Clinical Trials, Vol. 32, No. 5, pp. 741–746
Publisher
Elsevier
Publication Date
9 2011
DOI
10.1016/j.cct.2011.05.007
ISSN
1551-7144
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Analysis of VarianceBone Density Conservation AgentsCanadaChi-Square DistributionCommunity Health ServicesDiphosphonatesFemaleHumansImidazolesMulticenter Studies as TopicOsteoporosis, PostmenopausalProduct Surveillance, PostmarketingProspective StudiesRiskRisk AssessmentSurveys and QuestionnairesTime FactorsWomen's HealthZoledronic Acid